BioCentury | Dec 1, 2020
Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

...up $0.36 (24%) to $1.86 on Monday.TARGETSBtk – Bruton’s tyrosine kinaseEBV - Epstein-Barr virusPDK1 - Pyruvate dehydrogenase...
BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

...from systemic lupus erythematosus patients, tissue with high T cell infiltration had higher protein levels pyruvate dehydrogenase...
BioCentury | Jun 20, 2019
Distillery Therapeutics

MHCII nanoparticles for autoimmune hepatic diseases

...Parvus Therapeutics Inc. founder Pere Santamaria has developed nanoparticles coated with MHCII molecules displaying a PDH-derived...
...preclinical development for undisclosed autoimmune liver diseases. TARGET/MARKER/PATHWAY: Major histocompatibility complex class II (MHCII); pyruvate dehydrogenase (PDH...
...Calgary, Calgary, Alta. email: psantama@ucalgary.ca Sandi Wong Parvus Therapeutics Inc. University of Calgary Major histocompatibility complex class II (MHCII) Pyruvate dehydrogenase (PDH) Liver...
BioCentury | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

...signal of RSK2 activation. Source: Phoenix Molecular Designs MAPK (ERK) - MAP kinase; PDK - pyruvate dehydrogenase...
...Poly(ADP-ribose) polymerase PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 PDK - Pyruvate dehydrogenase...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...IDO1 - Indoleamine 2,3-dioxygenase 1 PD-1 (PDCD1; CD279) - Programmed cell death 1 PDK4 - Pyruvate dehydrogenase...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

...GLP-1R; Glucose-dependent insulinotropic polypeptide (GIP) receptor Insulin secretion pathway Unknown SAR438335 Peptide Sanofi (Euronext:SAN; NYSE:SNY) Pyruvate dehydrogenase...
BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

...IL-30 could help treat prostate cancer. University of Chieti-Pescara Distillery Therapeutics Preclinical news Prostate cancer Pyruvate dehydrogenase...
BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

...steps could include identifying and testing PDHA1 inhibitors in additional models of prostate cancer. TARGET/MARKER/PATHWAY: Pyruvate dehydrogenase...
...15, 2018 doi:10.1038/s41588-017-0026-3 CONTACT: Andrea Alimonti, University of Lugano, Lugano, Switzerland email: andrea.alimonti@ior.iosi.ch Claire Quang University of Lugano Pyruvate dehydrogenase...
BioCentury | Apr 7, 2017
Clinical News

CPI-613 regulatory update

...last year. CPI-613 is an analog of alpha-lipoic acid that targets the mitochondrial enzymes pyruvate dehydrogenase (PDH...
...alpha-ketoglutarate dehydrogenase. Cornerstone Pharmaceuticals Inc. , Cranbury, N.J. Product: CPI-613 Business: Cancer Alicia Parker CPI-613 Cornerstone Pharmaceuticals Inc. Pyruvate dehydrogenase (PDH...
BioCentury | Mar 25, 2017
Product Development

Pivotal meeting

...maintain high rates of replication and quickly repair damage following chemotherapy. The mitochondrial enzymes pyruvate dehydrogenase (PDH...
...down cancer.” BioCentury (2011) McCallister, E. “AML advances.” BioCentury (2016) Virginia Li, Staff Writer CPI-613 Cornerstone Pharmaceuticals Inc. Pyruvate dehydrogenase (PDH...
Items per page:
1 - 10 of 48